Hemogenyx Pharma Stock Price, News & Analysis

Hemogenyx Pharmaceuticals (LSE:HEMO) announced the exercise of warrants for 250,000 new ordinary shares. The warrants, originally granted on May 8, 2025, had their exercise price adjusted to 180p per share, resulting in subscription monies of £450,000 received by the company.

Following admission of these shares and including the previously announced 316,667 new ordinary shares from August 26, 2025, the company's total issued shares and voting rights will increase to 5,293,896. The new shares are expected to be admitted to trading on the LSE main market on September 9, 2025.

Hemogenyx Pharmaceuticals (OTC:HOPHF) has secured £620,000 in funding through the issuance of convertible loan notes (CLNs) to support its ongoing clinical trial of HG-CT-1, a CAR-T cell therapy for relapsed or refractory acute myeloid leukemia.

The CLNs were issued at a fixed conversion price of £5.30 per share and are non-interest bearing. They will automatically convert into 116,982 Ordinary Shares following an increase in the Company's headroom restrictions under FCA's Prospectus Rules, expected around November 15, 2025.

Hemogenyx Pharmaceuticals (LSE: HEMO) has announced its decision to re-appoint PKF Littlejohn LLP as its external auditor for the financial year ending December 2025 and beyond. The decision follows a mandatory audit tender process required for public interest entities every ten years. The appointment will coincide with the mandatory lead audit partner rotation and requires shareholder approval at the company's 2026 Annual General Meeting.

The clinical-stage biopharmaceutical company, headquartered in London with US subsidiaries in New York City, focuses on developing treatments for blood and autoimmune diseases. The audit tender process was overseen by the Audit Committee, with detailed evaluation criteria to be disclosed in the Group's 2025 Annual Report & Accounts.

Hemogenyx Pharmaceuticals (LSE:HEMO) has successfully raised £570,000 through an allotment of 316,667 new ordinary shares at 180p per share, representing a premium to the market price. The shares were initially subscribed by CEO Vladislav Sandler and will be directed to a small group of investors.

The funding will support the continuation of the company's Phase I clinical trials for HG-CT-1, a Chimeric Antigen Receptor T-cell therapy targeting relapsed/refractory acute myeloid leukemia in adults. The investors will also receive one-for-one warrants exercisable for 36 months at 180p.

Following admission, expected around September 4, 2025, the company's total issued shares will be 5,043,896. The premium-priced fundraising reflects investor confidence in Hemogenyx's progress and long-term prospects.

Hemogenyx Pharmaceuticals (LSE:HEMO, OTC:HOPHF) has successfully treated the third patient in its Phase I clinical trial of HG-CT-1, a proprietary CAR-T cell therapy for relapsed/refractory acute myeloid leukemia (R/R AML). This marks the completion of the first adult dose cohort, achieved after receiving special FDA permission under exceptional circumstances.

The company reported encouraging early results, with the first two patients remaining alive at six and three months post-treatment. Following this milestone, Hemogenyx plans to advance to a second adult dose cohort with twice the initial dose and initiate a pediatric trial arm. The Phase I trial aims to evaluate safety and secondary endpoints including anti-leukemic activity, survival rates, and duration of response.

Hemogenyx Pharmaceuticals (OTC:HOPHF) has secured £250,000 through a strategic share placement, issuing 133,690 new ordinary shares at 187p per share, representing a premium to the current market price. The shares will be initially allotted to CEO Vladislav Sandler, who will then transfer them to a group of new investors.

The funding will support the continuation of the company's Phase I clinical trials for HG-CT-1, their Chimeric Antigen Receptor T-cell therapy targeting relapsed/refractory acute myeloid leukemia in adults. The company reports that the first two patients have completed four-week safety trials with encouraging early efficacy signs.

The deal includes one-for-one warrants exercisable at 187p for 36 months. Upon admission of the new shares, expected around August 7, 2025, the total number of issued shares will be 4,727,229.

Hemogenyx Pharmaceuticals (LSE:HEMO, OTC:HOPHF) has secured a $120,000 G-Rex® grant from ScaleReady, in partnership with Wilson Wolf Manufacturing and Cell Ready. The grant will support the optimization and scale-up of manufacturing for HG-CT-1, the company's lead CAR-T product candidate currently in Phase I trials for relapsed/refractory acute myeloid leukemia.

The funding will enable development of a closed-system, G-Rex®-based manufacturing platform, aimed at reducing production complexity, enhancing regulatory compliance, and lowering per-patient manufacturing costs. The grant includes technical consulting support in lean bioprocessing, regulatory strategy, and process engineering to support future clinical and commercial-scale manufacturing.

Hemogenyx Pharmaceuticals (HOPHF) has received FDA clearance to expand its Phase I clinical trial of HG-CT-1, a proprietary CAR-T therapy for relapsed/refractory acute myeloid leukemia (R/R AML), to include pediatric and adolescent patients. The FDA's 30-day review period concluded without a clinical hold, allowing the company to proceed with Institutional Review Board submissions and site activation procedures for pediatric cohorts. This expansion broadens the potential therapeutic reach of HG-CT-1 and represents a significant milestone in the company's development program, particularly in addressing the needs of younger patients with this aggressive form of leukemia.

Hemogenyx Pharmaceuticals has raised £451,250 through a placing of 250,000 new ordinary shares at 180.5p per share to CEO Vladislav Sandler, who will direct their issue to an institution for immediate sale to a purchaser. The purchaser will receive one-for-one warrants exercisable for 36 months at 270 pence. The funding will support the continuation of Phase I clinical trials for HG-CT-1, the company's CAR-T cell therapy targeting relapsed/refractory acute myeloid leukemia in adults. Two patients have already been infused with HG-CT-1. Upon admission of the new shares, expected around June 13, the total number of issued shares will be 4,593,539. The placement was completed at a premium to market price, demonstrating investor confidence in Hemogenyx's long-term potential.